中国临床药理学杂志2025，Vol.41Issue(8)：1051-1055,5.DOI:10.13699/j.cnki.1001-6821.2025.08.001
依洛尤单抗联合瑞舒伐他汀用于PCI术后急性心肌梗死患者的临床研究
Clinical trial of evolocumab combined with rosuvastatin in the treatment of patients with acute myocardial infarction after PCI
摘要
Abstract
Objective To observe the clinical efficacy and safety of evolocumab injection combined with rosuvastatin tablets in the treatment of patients with acute myocardial infarction(AMI)after percutaneous coronary intervention(PCI).Methods The AMI patients were randomly divided into control group and treatment group.The control group was given oral rosuvastatin at an initial dose of 10 mg daily,if the level of low-density lipoprotein cholesterol(LDL-C)＞1.4 mmol·L-1,the dose was increased to 20 mg daily.On the basis of control group,the treatment group received evolocumab 140 mg,subcutaneous injection of the abdomen,once every 2 weeks.Two groups were treated for 6 months.The clinical efficacy,myocardial injury markers,lipid metabolism parameters,overall incidence of cardiovascular events and safety were compared between two groups.Results Treatment group were enrolled 55 cases,2 cases dropped out,and 53 cases were finally included in the statistical analysis.Control group were enrolled 53 cases,1 case dropped out,and 52 cases were finally included in the statistical analysis.After treatment,the total effective rates of treatment and control groups were 92.45％(49 cases/53 cases)and 78.85％(41 cases/52 cases),with statistically significant difference(P＜0.05).After treatment,the levels of high-sensitivity cardiac troponin were(2.02±0.61)and(2.78±0.73)ng·L-1,the levels of creatine kinase-MB were(38.90±6.47)and(50.05±6.15)U·L-1,the levels of total cholesterol were(2.27±0.15)and(3.15±0.19)mmol·L-1,the levels of triglycerides were(1.61±0.12)and(1.77±0.17)mmol·L-1,the levels of LDL-C were(1.25±0.15)and(2.08±0.13)mmol·L-1,the overall incidences of cardiovascular events were 5.77％and 16.98％,respectively.The differences of above indexes were statistically significant(all P＜0.05).The adverse drug reactions of treatment group were skin rash,elevated creatine kinase and liver injury,while those in the control group were nausea and vomiting,skin rash and liver injury.The total incidences of adverse drug reactions in treatment and control groups were 9.43％and 5.77％,without statistically significant difference(P＞0.05).Conclusion Evolocumab injection combined with rosuvastatin tablets has a definitive clinical efficacy in the treatment of patients with AMI after PCI,which can significantly improve cardiac function,reduce the risk of myocardial injury and cardiovascular events,with good safety.关键词
依洛尤单抗注射液/瑞舒伐他汀片/经皮冠状动脉介入治疗/急性心肌梗死/心肌损伤/心血管事件Key words
evolocumab injection/rosuvastatin tablet/percutaneous coronary intervention/acute myocardial infarction/myocardial injury/cardiovascular event分类
医药卫生引用本文复制引用
何仲春,龙秋香,董博..依洛尤单抗联合瑞舒伐他汀用于PCI术后急性心肌梗死患者的临床研究[J].中国临床药理学杂志,2025,41(8):1051-1055,5.基金项目
湖南省卫生健康委员会科研计划基金资助项目(202203012990) （202203012990）
长沙市第一医院院级科研基金资助项目(Y2023-22) （Y2023-22）
